Tirzepatide and semaglutide are often compared as if you simply pick the stronger one, but that is not how the choice works. The plain difference is mechanism: semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP and GLP-1 receptor agonist, so it engages a second pathway as well. Here is what that distinction means, how a physician weighs it, and why the labs come before the molecule.
How the two mechanisms differ (glp-1 dual agonist)
GLP-1 is a hormone your gut releases after eating; it supports the body’s own signals around blood sugar and appetite, which is why the class is used in medical weight care. Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a glp-1 dual agonist: it adds the GIP receptor, a second incretin pathway involved in how the body handles glucose and fat. Engaging two receptors is a real mechanistic difference, but more pathways is not automatically the right answer for a given person. Which mechanism fits depends on the individual, and that judgment belongs to a licensed physician, not to a comparison chart.
How a physician chooses between them (semaglutide mechanism)
There is no universal “start here” rule. A physician weighs your history, your current markers, how your body tolerates a given medication, any prior response, and your overall metabolic picture, then decides what, if anything, is appropriate. Tolerance matters as much as mechanism, because the most relevant medication is the one a person can stay on under physician supervision. Dose is individualized too: GLP-1 medications are typically introduced low and adjusted over time by the physician, not chosen by the patient. So “tirzepatide vs semaglutide” is a clinical decision read against your specific data, which is exactly why the data comes first.
you are
Add what fits. A physician reviews every order and arranges your consult and labs at checkout. Browse the shop →
Why the metabolic panel is read first (glp-1 weight medication)
Before any conversation about a glp-1 weight medication, a metabolic panel measures where your metabolism actually sits. The core markers are HbA1c (your roughly three-month glucose average), fasting glucose and fasting insulin (insulin resistance can hide behind a normal glucose, which is why insulin is read too), ApoB and a lipid view (cardiometabolic context), and ALT (the liver and metabolic health tend to track together). These are measurements, not outcomes. They describe context and give a physician a baseline to compare against later. For the full breakdown of each marker, see what a GLP-1 metabolic panel measures.
Reading them together (labs before molecules)
The choice between tirzepatide and semaglutide is never made on the molecule name alone. It is made on the markers, your history, and your tolerance, read together, and then revisited with the same panel during care so change is measured rather than assumed. This is the “labs before molecules” idea: you measure first, across enough markers to see the real metabolic pattern, before anyone decides which GLP-1 medication, if any, fits, and at what dose. The Telos Panel exists so that decision is made in context. (See the Telos Panel and what a full panel covers.)
What your physician does with this
At Telos, the information you provide and the panel you complete are reviewed by a licensed physician through the affiliated medical group. They read your metabolic markers alongside your history and decide what, if anything, fits, including whether a GLP-1 medication is appropriate at all, and if so, which one and at what starting dose. If care is prescribed, it is overseen by a physician and monitored with labs over time. The physician may or may not establish a treatment relationship. Telos is a marketing and advertising company; it does not practice medicine, prescribe, or employ physicians. Nothing here is medical advice.
